Researchers at Johns Hopkins Bloomberg School of Public Health have found that people with type 1 diabetes who take GLP-1 receptor agonists experience significant improvements in both cardiovascular and kidney health outcomes. The findings add to growing evidence that these medications, originally developed for type 2 diabetes and weight management, may offer broader therapeutic benefits than previously understood.
GLP-1 receptor agonists like semaglutide and liraglutide work by mimicking a hormone that regulates blood sugar and appetite. While they’ve been approved for type 2 diabetes for years, their use in type 1 diabetes has been more limited and remains off-label in most cases. Type 1 diabetes patients face elevated risks of cardiovascular disease and kidney complications throughout their lives, making interventions that address these concerns particularly valuable.
The Johns Hopkins research suggests that type 1 diabetes patients taking these medications may experience protective effects on both heart and kidney function, potentially reducing the risk of serious complications that have historically plagued this patient population. These organ systems are particularly vulnerable in diabetes due to the cumulative effects of blood sugar fluctuations and metabolic stress over time.
For the estimated 1.9 million Americans living with type 1 diabetes, treatment options have traditionally focused primarily on insulin management and blood sugar control. The potential for GLP-1 medications to provide additional cardiovascular and renal protection could represent a meaningful expansion of the therapeutic toolkit available to these patients and their healthcare providers.
As research in this area continues to evolve, clinicians may need to reconsider treatment protocols for type 1 diabetes patients who are at elevated risk for heart or kidney disease. However, patients should consult with their endocrinologists before making any changes to their diabetes management plans, as GLP-1 use in type 1 diabetes requires careful monitoring and individualized assessment.
